Novogenia Aktie
| 7,55EUR | 0,15EUR | 2,03% |
WKN DE: A3C35W / ISIN: DE000A3C35W0
Personal
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Personal am Ende des Jahres | 0 | 0 | 0 | 0 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,00 | 0,00 | 0,00 | 0,00 |
Bilanz (in Mio. EUR) - Aktiva
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Summe Umlaufvermögen | 157 | 214 | 132 | 111 |
| Summe Anlagevermögen | 5 | 9 | 47 | 42 |
| Summe Aktiva | 162 | 224 | 179 | 153 |
Bilanz (in Mio. EUR) - Passiva
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Summe Fremdkapital | 93 | 110 | 85 | 47 |
| Summe Eigenkapital | 69 | 114 | 94 | 106 |
| Summe Passiva | 162 | 224 | 179 | 153 |
Adresse
| Brienner Strasse 7, 80333 Munich | |
| Telefon | +49 (8920) 500-450 |
| Internet | http://darwin-biotech.com |
Management
|
Caroline Probst
Member-Supervisory Board |
|
Christian Dreyer
Chairman-Supervisory Board |
|
Daniel Wallerstorfer
CEO & Chairman-Management Board |
|
Felix Bausch
Chief Investment Officer & Member-Management Board |
|
Florian Renner
Vice Chairman-Supervisory Board |
|
Matthias Probst
CFO & Member-Management Board |